Investors here are not interested in daily price swings. The are looking at the long term success ..and based on positive data related to the clinical trials. You sound like a rookie!
Thanks Fezz: When can we hear about trial progress and/or any data (with the PegpH20/Keytruda trial)?
It really isnt when you dont have any cash to bring the pipeline forward. However, if they do secure any non dilutive (and significant) funding...you will be correct.
Call Roche's investor relations department. Halo doesnt own Mabthera (and it doesnt control what markets they enter either). Help yourself.....and stop relying on others to do proper due diligence.
New platform and IND coming shortly. I hope their current drug is not a bust. I am getting concerned with all of the Insider selling (but who knows if they need tax loss selling).
Lets hope the stock market has made a major turn upward; so we can can OncoVista funded with fresh equity capital. I think the next 5 weeks heading into year end will be favorable to get the funding completed.
I believe the company will seriously (and may have to) consider a takeover proposal (bankruptcy is still a year or two away). It terms of worth; it really depends on what success lies within their current pipeline. I think $7-$8 seems fair; but it will easily go over $10 if they have a successful Phase II/III.
Bruce owns over 32mm shares. I hope this is just tax loss selling (but it certainly cratered the stock price over the last few days). If he lets up the peddle ..maybe we will grind back higher once again.
Yeah! They should probably just announce sale of the company. I am hoping the some big Pharma. will take this out at like $7-$8 a share (or maybe $10-$12 if at least one of their drug indications is working).
Enrolling more than 100 patients to date in Stage 2 of Halozyme Study 202 of investigational new drug PEGPH20 in metastatic pancreatic ductal adenocarcinoma patients. Halozyme plans to complete its target enrollment of 114 patients by the end of 2015 and present results of the study in the second half of 2016.
Enrolling in 4 other trials. Just have to wait the news....Q1 16 IND. for new platform pending (simple a very speculative play). I think the new BOD hire could have some interesting possibilities (he specializes in funding later stage biotech companies...just what the doctored ordered here).